Substance abuse in Europe has been a prevalent issue since channels for cannabis, heroin and amphetamines were established throughout the course of the 1970s and 1980s. Europe is a key market for drugs of abuse, supplied both from domestic producers and traffickers globally with an estimated value of €24 Billion.
Whilst offline markets still prevail, the continuous increase of demand coupled with the conception of online drug marketplaces have contributed to the sheer scale of the global drug problem. As a result, drug related hospital admissions have significantly increased, with estimated 5-10% of hospital admissions arising due to drug related problems (DRP).
It is reported that more than 92 million adults in the European Union are estimated to have tried illicit drugs during their lifetime, with usage being more frequently reported by males than females. (56 million and 36.3 million respectively.)
Last year, it was noted that young adults were among those most at risk, with an estimated 18.9 million young adults (aged 15-34) reporting to have used drugs in the previous year, twice as many males than females reporting doing so.
The importance of drug testing.
With global reports indicating that drug use remains to be a prevalent issue across Europe. It is of the utmost importance that accurate, innovative technology is available to medical practitioners in order to correctly treat patients who have been admitted to hospital as a result of drug misuse.
Using our revolutionary Biochip Array Technology, the Evidence MultiSTAT is an automated analyser that enables on-site simultaneous detection of up to 21 classical, prescription and synthetic drugs from a single sample. Designed to work across a variety of matrices including our CE marked urine and whole blood panel, the patented multi-analyte testing platform provides a complete immunoassay profile within minutes, changing the landscape of drug detection forever.